Economic evaluation of epinephrine auto-injectors for peanut allergy

Publication date: Available online 19 June 2017
Source:Annals of Allergy, Asthma & Immunology
Author(s): Marcus Shaker, Katherine Bean, Marylee Verdi
BackgroundThree commercial epinephrine auto-injectors were available in the United States in the summer of 2016: EpiPen, Adrenaclick, and epinephrine injection, USP auto-injector.ObjectiveTo describe the variation in pharmacy costs among epinephrine auto-injector devices in New England and evaluate the additional expense associated with incremental auto-injector costs.MethodsDecision analysis software was used to evaluate costs of the most and least expensive epinephrine auto-injector devices for children with peanut allergy. To evaluate regional variation in epinephrine auto-injector costs, a random sample of New England national and corporate pharmacies was compared with a convenience sample of pharmacies from 10 Canadian provinces.ResultsAssuming prescriptions written for 2 double epinephrine packs each year (home and school), the mean costs of food allergy over the 20-year model horizon totaled $58,667 (95% confidence interval [CI] $57,745–$59,588) when EpiPen was prescribed and $45,588 (95% CI $44,873–$46,304) when epinephrine injection, USP auto-injector was prescribed. No effectiveness differences were evident between groups, with 17.19 (95% CI 17.11–17.27) quality-adjusted life years accruing for each subject. The incremental cost per episode of anaphylaxis treated with epinephrine over the model horizon was $12,576 for EpiPen vs epinephrine injection, USP auto-injector. EpiPen costs were lowest at Canadian pharmacies ($96, 95% CI $85–$107). There was price consistency between corporate and independent pharmacies throughout New England by device brand, with the epinephrine injection, USP auto-injector being the most affordable device.ConclusionCost differences among epinephrine auto-injectors were significant. More expensive auto-injector brands did not appear to provide incremental benefit.



http://ift.tt/2ryIbL3